Overview

The IMmunotherapy Pleural 5-ALA PDT

Status:
Not yet recruiting

Trial end date:
2025-09-01

Target enrollment:

Participant gender:

Summary

Pilot study of the feasibility of an innovative multimodal treatment combining intrapleural photodynamic therapy with videothoracoscopy followed by adjuvant immunotherapy with anti-PD-1 Nivolumab antibodies in patients with malignant pleural mesothelioma

Phase:

Phase 2

Details

Lead Sponsor:

University Hospital, Lille

Collaborator:

Bristol-Myers Squibb

Treatments:

Nivolumab